News

Article

ProQR Therapeutics offers update on sale of ophthalmic assets

Author(s):

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

 According to a news release, the completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology personnel from ProQR. (Image courtesy of Adobe Stock)

According to a news release, the completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology personnel from ProQR. (Image courtesy of Adobe Stock)

ProQR Therapeutics N.V. today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

According to a news release, the completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology personnel from ProQR.

According to ProQR, some of the ophthalmology personnel decided not to continue employment at Théa. As a result, the closing condition for the transaction cannot be fulfilled and Théa terminated the agreement.

Daniel A. de Boer, founder and CEI of ProQR, said while the company was disappointed the sale of the ophthalmology programs to Théa will not proceed, the primary focus at ProQR remains on the company’s Axiomer RNA editing platform.

“We look forward to advancing our wholly owned pipeline with an initial focus on targets for cholestatic and cardiovascular diseases, in addition to our partnership with Lilly, as we work to develop a new class of therapies for patients with high unmet need,” de Boer said in a news release.

ProQR is developing a next-generation RNA technology called Axiomer, which the company noted in a news release uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.